Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target reduced by BMO Capital Markets from $111.00 to $100.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “market perform” rating on the stock. BMO Capital Markets’ target price indicates a potential downside of 6.69% from the stock’s previous close. […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its target price dropped by stock analysts at Mizuho from $116.00 to $114.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price points to a potential upside of 6.37% from the stock’s current price. […]
Gulf International Bank UK Ltd lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 22.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,879 shares of the company’s stock after selling 2,821 shares during the quarter. Gulf International Bank UK […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) – Equities researchers at William Blair raised their Q4 2023 EPS estimates for shares of Neurocrine Biosciences in a research report issued to clients and investors on Wednesday, October 18th. William Blair analyst M. Minter now anticipates that the company will post earnings of $1.37 per share for […]
Linden Thomas Advisory Services LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,533 shares of the company’s stock after acquiring an additional 138 shares during the quarter. Linden […]